Quarterly Updates20 Jan 2026, 02:17 pm
Senores Pharmaceuticals Reports Strong Q3 & 9M FY26 Performance with 105% Profit After Tax Growth
AI Summary
Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, announced its un-audited financial results for the 3rd quarter and nine-months year ended 31st December 2025. The company reported a significant increase in income, EBITDA, and profit after tax for both Q3FY26 and 9MFY26. Key highlights include improved cash flow from operations, a robust pipeline of ANDAs, strong growth in emerging markets, and the acquisition of Apnar Pharmaceuticals. The company is focused on expanding its ANDA portfolio, CDMO/CMO segment, and Branded Generics business, aiming to deliver sustained growth.
Key Highlights
- Q3FY26 Consolidated Financial Highlights: Income - Rs. 175 Crs, EBITDA - Rs. 54 Crs, Profit After Tax - Rs. 34 Crs, representing a Y-o-Y growth of 64%, 86%, and 105% respectively
- 9MFY26 Consolidated Financial Highlights: Income - Rs. 474 Crs, EBITDA - Rs. 138 Crs, Profit After Tax - Rs. 85 Crs, representing a Y-o-Y growth of 65%, 87%, and 110% respectively
- Improved Cash Flow from Operations: Q3FY26 - Rs. 19 crs, 9MFY26 - Rs. 51 crs
- Robust pipeline of ANDAs: 46 approved ANDAs covering 137 strengths, 22 additional ANDAs under development with 50+ strengths
- Significant growth in Emerging Markets: Revenue growth of ~48% for Q3FY26 on a Y-o-Y basis, EBITDA margin of ~13% for Q3FY26 compared to ~1% in Q3FY25